P53 as a prognostic marker for bladder cancer : a meta-analysis and review
BACKGROUND: P53 is the most widely investigated molecular marker in bladder cancer. We aimed to review comprehensively the evidence for use of changes in P53 to predict bladder-cancer recurrence, progression, and mortality.
METHODS: We reviewed 168 publications from 117 studies. Estimates of significance were extracted from association tests, and hazard ratios with 95% CI from actuarial curves and Cox regression analyses. A meta-analysis was done on the studies that applied Cox models.
FINDINGS: The methods used to assess significance varied widely between studies. 27% (nine of 34) of studies that assessed the prognostic value of P53 overexpression in recurrence by use of multivariate tests showed a significant association. The corresponding values for progression and mortality were 50% (12 of 24) and 29% (ten of 35), respectively. In the studies that used Cox models, the overall risk of recurrence was 1.6 (95% CI 1.2-2.1), of progression was 3.1 (1.9-4.9), and of mortality was 1.4 (1.2-1.7). These findings could be overestimates because of publication and reporting bias.
INTERPRETATION: After 10 years of research, evidence is not sufficient to conclude whether changes in P53 act as markers of outcome in patients with bladder cancer.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2005 |
|---|---|
| Erschienen: |
2005 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
The Lancet. Oncology - 6(2005), 9 vom: 30. Sept., Seite 678-86 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Malats, Núria [VerfasserIn] |
|---|
| Themen: |
Biomarkers, Tumor |
|---|
| Anmerkungen: |
Date Completed 27.09.2005 Date Revised 18.03.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM157469638 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM157469638 | ||
| 003 | DE-627 | ||
| 005 | 20231223080245.0 | ||
| 007 | tu | ||
| 008 | 231223s2005 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0525.xml |
| 035 | |a (DE-627)NLM157469638 | ||
| 035 | |a (NLM)16129368 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Malats, Núria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a P53 as a prognostic marker for bladder cancer |b a meta-analysis and review |
| 264 | 1 | |c 2005 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 27.09.2005 | ||
| 500 | |a Date Revised 18.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: P53 is the most widely investigated molecular marker in bladder cancer. We aimed to review comprehensively the evidence for use of changes in P53 to predict bladder-cancer recurrence, progression, and mortality | ||
| 520 | |a METHODS: We reviewed 168 publications from 117 studies. Estimates of significance were extracted from association tests, and hazard ratios with 95% CI from actuarial curves and Cox regression analyses. A meta-analysis was done on the studies that applied Cox models | ||
| 520 | |a FINDINGS: The methods used to assess significance varied widely between studies. 27% (nine of 34) of studies that assessed the prognostic value of P53 overexpression in recurrence by use of multivariate tests showed a significant association. The corresponding values for progression and mortality were 50% (12 of 24) and 29% (ten of 35), respectively. In the studies that used Cox models, the overall risk of recurrence was 1.6 (95% CI 1.2-2.1), of progression was 3.1 (1.9-4.9), and of mortality was 1.4 (1.2-1.7). These findings could be overestimates because of publication and reporting bias | ||
| 520 | |a INTERPRETATION: After 10 years of research, evidence is not sufficient to conclude whether changes in P53 act as markers of outcome in patients with bladder cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 700 | 1 | |a Bustos, Aurelia |e verfasserin |4 aut | |
| 700 | 1 | |a Nascimento, Cristiane M |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Rivas, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Puente, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Kogevinas, Manolis |e verfasserin |4 aut | |
| 700 | 1 | |a Real, Francisco X |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Oncology |d 2000 |g 6(2005), 9 vom: 30. Sept., Seite 678-86 |w (DE-627)NLM117859516 |x 1474-5488 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2005 |g number:9 |g day:30 |g month:09 |g pages:678-86 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2005 |e 9 |b 30 |c 09 |h 678-86 | ||